List view / Grid view
14 March 2014 | By Boehringer Ingelheim
More than 73 percent of physicians surveyed said the complexity of Type 2 Diabetes is underestimated...
11 March 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces the enrolment of the 10,000th patient with atrial fibrillation (AF) into GLORIA™-AF, one of the largest AF registry programmes currently running worldwide...
6 March 2014 | By Boehringer Ingelheim
More than 100 countries have now approved Boehringer Ingelheim’s Pradaxa® for the prevention of stroke and systemic embolism for adult patients with the most common sustained heart rhythm condition...
3 March 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® inhaler was effective and well tolerated in patients across asthma severities...
17 February 2014 | By Boehringer Ingelheim
Boehringer Ingelheim Fremont Inc. received the East Bay Innovation Award in recognition for its contribution to the East Bay's culture of innovation...
7 January 2014 | By Boehringer Ingelheim
Under the terms of the agreement, Crystal will receive an upfront technology access fee and research funding for each program...
16 December 2013 | By Boehringer Ingelheim,
"These data are encouraging as they demonstrate that HCV genotype-1 infected patients irrespective of the presence of the common HCV Q80K variant..."
10 December 2013 | By Boehringer Ingelheim
The efficacy and safety profile of Pradaxa® (dabigatran etexilate) was maintained regardless of patient characteristics...
3 December 2013 | By Boehringer Ingelheim
Boehringer Ingelheim (BI) and Eli Lilly and Company today announced new data1 from a Phase IV study evaluating linagliptin (5 mg) as monotherapy and in combination with metformin (1500 or 2000 mg) in treatment-naive adults with newly diagnosed (<12 months) uncontrolled Type 2 Diabetes (T2D).
2 December 2013 | By Boehringer Ingelheim
The survey was developed in partnership with the International Diabetes Federation (IDF) and will include more than 10,000 people with T2D and more than 6,500 treating-physicians...
26 November 2013 | By Boehringer Ingelheim
The application for European marketing authorisation of faldaprevir* has been fully validated and granted accelerated assessment by the European Medicines Agency...
19 November 2013 | By Boehringer Ingelheim
Pradaxa® is the only novel oral anticoagulant with more than 6 years of long-term data supporting its beneficial role for stroke prevention...
15 November 2013 | By Boehringer Ingelheim
"Run for Diabetes" raises €15,000 towards supporting "Life for a Child Programme..."
13 November 2013 | By Boehringer Ingelheim
"Our extensive studies have demonstrated that tiotropium Respimat® has the potential to be an effective new treatment..."
11 November 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announces clinical experience with its angiotensin II receptor blocker (ARB) has reached 50 million patient-years of real world experience...
